Text Size

Time Course of Procalcitonin and C Reactive Protein in Septic Patients Under Treatment With Corticosteroids

This study has been completed.
Sponsor:
Collaborator:
Brahms SA, D-16761 Hennigsdorf bei Berlin
Information provided by:
Ospedale Regionale Bellinzona e Valli
ClinicalTrials.gov Identifier:
NCT00141973
First received: September 1, 2005
Last updated: May 13, 2008
Last verified: May 2008
History of Changes
  Purpose

A systemic treatment with corticosteroids has been advocated for various bacterial infectious diseases. Since the production of CRP is down-regulated by corticosteroids, a smaller increase or a more rapid decrease of this acute phase protein will:

  1. suggest attenuated systemic inflammation, but
  2. does not necessarily reflect adequate therapy of the infection.

For several reasons (good diagnostic tool for sepsis, induction not decreased by immunosuppressive therapy), procalcitonin could be a better marker for activity of sepsis in patients under corticosteroids. As this issue has not yet been examined the investigators will prospectively study the time-course of PTC and CRP in a well-defined septic patient group, that in adjunction to antibiotic therapy also received systemic corticosteroid treatment and compare it to a similar group without corticosteroid treatment.


Condition
Sepsis

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Sepsis Steroids
U.S. FDA Resources

Further study details as provided by Ospedale Regionale Bellinzona e Valli:

Study Start Date: November 2004
Estimated Study Completion Date: December 2005
  Eligibility

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Acute exacerbation of chronic obstructive pulmonary disease (COPD) due to bacterial pneumonia

Exclusion Criteria:

  • Chronic systemic use of corticosteroids
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00141973

Locations
Switzerland
Ospedale Regionale Bellinzona e Valli
Bellinzona, Ticino, Switzerland, 6500
Sponsors and Collaborators
Ospedale Regionale Bellinzona e Valli
Brahms SA, D-16761 Hennigsdorf bei Berlin
Investigators
Principal Investigator: Andreas Perren, MD Ospedale Regionale Bellinzona e Valli, CH-6500 Bellinzona
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00141973     History of Changes
Other Study ID Numbers: CE1408
Study First Received: September 1, 2005
Last Updated: May 13, 2008
Health Authority: Switzerland: Swissmedic

Keywords provided by Ospedale Regionale Bellinzona e Valli:
Procalcitonin
Sepsis
Corticosteroids

Additional relevant MeSH terms:
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on May 22, 2013